India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India-focused Independent Equity Research Analyst

Experienced (7 years +) in Sector-Specific Deep Dives and Comprehensive Company Research.

With a sharp focus on the Indian market, I specialize in providing in-depth analysis and insights to investors. Whether it's dissecting various sectors to identify emerging trends or conducting thorough fundamental research on individual companies, I'm dedicated to uncovering valuable opportunities and delivering actionable intelligence.

Passionate about navigating the nuances of the Indian equity landscape, I thrive on deciphering complex market dynamics and distilling them into clear, concise insights. 

While covering a sector or company-specific research, I cover the following :
1. Brief about company/sector
2.  Overall Industry landscape - History, Present and Future trends
3. Thesis and Anti-Thesis
4. Valuations
5. Financial & Forensic Analysis
6. Management Review
7. Key Monitorable Events
8. Guidance and Future Way Ahead

India Equity Analyst - Fundamental & Thematic

Sudarshan Chemical: Heubach Acquisition Starts Delivering Results

Sai Parenterals: From Injectables Niche to a Global Formulations Platform

Concord Biotech: A Fermentation Leader's Setting Up for a Cleaner FY27

Swiggy: Discipline Over Discounting Becomes the Real Story

PVR Inox: The OTT Threat Is Played Out, Growth Is Back

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>Gufic Biosciences, a specialty pharma company focused on complex injectables, closed FY26 with INR 940.5 crore revenue, flat profit and a record Q4.</li>
<li>The Indore plant reached 30% utilisation and turned EBITDA-positive, while exports and working capital are shifting from drag factors to growth levers.</li>
<li>FY27 performance depends on Indore scale-up, export approvals and cleaner receivables, management targets around 15% revenue growth and near-18% EBITDA margin.</li>
</ul>


Gufic Biosciences, a specialty pharma company focused on complex injectables, closed FY26 with INR 940.5 crore revenue, flat profit and a record Q4.
The Indore plant reached 30% utilisation and turned EBITDA-positive, while exports and working capital are shifting from drag factors to growth levers.
FY27 performance depends on Indore scale-up, export approvals and cleaner receivables, management targets around 15% revenue growth and near-18% EBITDA margin.


Gufic Biosciences: Indore Plant Ramp-Up Sets the Stage for FY27 Recovery